Staining of Daudi cells with 0.25 μg of Purified Mouse IgG2b Iso Cntrl (cat. 14-4732) (open histogram) or 0.25 μg of Purified anti-human TCL1 (1-21) (colored histogram) followed by Biotin Anti-Mouse IgG (cat. 13-4013)and SAv-PE (cat. 12-4317). Total viable cells were used for analysis.
Contents: Affinity Purified anti-human TCL1 (T Cell Leukemia/Lymphoma 1) Catalog Number: 14-6699 Formulation: Phosphate buffered saline, pH 7.2, less than or equal to 0.09% NaN3 Clone: eBio1-21 (1-21) Host/Isotype: Mouse IgG2b, κ Storage Conditions: Store at 4°C. Avoid repeated freeze/thaw cycles.
Product Options
Cat. No.
Size
Price
Add Qty to Cart
14-6699-80
25 ug
14-6699-82
100 ug
Note: Several countries will continue to be supplied via distributors. Country specific prices may apply.
Flow Cytometry Product Notes: Test Sizes: To accommodate multicolor flow cytometry, eBioscience is in the process of reducing test size volumes from 20 µl to 5 µl. Please check your antibody vial for the recommended test size. Fluorochrome Replacements: eBioscience is in the process of replacing all Pacific Blue® and APC-Alexa Fluor® 750 conjugated products with eFluor™ 450 and APC-eFluor™ 780 conjugated products, respectively.
Description
The eBio1-21 antibody reacts with human T cell leukemia/lymphoma 1 (TCL1), a 14 kDa proto-oncogene product with a suggested role in intracellular regulation of T cell signalling. TCL1 was identified as the oncogene located at the 14q32.1 chromosome breakpoint region in T-cell prolymphocytic leukemia (T-PLL). In T-PLL, TCL1 is overexpressed as a result of an inversion or a reciprocal translocation, by juxtaposition to the T-cell receptor promoter/enhancer elements. TCL1 binds to the pleckstrin homology domain of Akt (protein kinase B) family proteins, which facilitates Akt dimerization and activity. By increasing Akt activity TCL1 may enhance the serine/threonine phosphorylation of major Akt signaling substrates, such as Ikk complex, mTOR, BAD, p70S6 kinase, FOXO transcription factors, and GSK3β. These substrates regulate cellular differentiation, growth, survival, and metabolism.
Besides its tumorigenic role in T-PLL, TCL1 is normally expressed in the CD3-CD4-CD8- subset of thymic precursors in the T cell lineage, the plasmacytoid subset of dendritic cells, stimulated (not resting) mature T cells, and B cells up to the germinal center stage of maturation. TCL1 is inappropriately expressed by chromosome rearrangements that lead to pre-malignant clonal T cell expansions and mature T cell tumors. TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia (CLL).
Applications Reported
For research use only, not for diagnostic or therapeutic use. This eBio1-21 (1-21) antibody has been reported for use in intracellular staining followed by flow cytometric analysis, immunoprecipitation, immunoblotting (WB), and immunohistology staining of paraffin embedded tissue sections. (Fluorochrome conjugated eBio1-21 (1-21) is recommended for use in intracellular flow cytometry.)
Applications Tested
This eBio1-21 (1-21) antibody has been tested by western blot analysis of Daudi cell lysates and intracellular staining followed by flow cytometric analysis of Daudi cells. For flow cytometry, this can be used at less than or equal to 0.5 μg per 100 μl blood (or per 1 million cells in 100 μl total staining volume). It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.
References
Herling M, Patel KA, Teitell MA, Konopleva M, Ravandi F, Kobayashi R, Jones D. High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood. 2008 Jan 1;111(1):328-37. Epub 2007 Sep 21. (eBio1-21, IHC, WB PubMed)
Herling, M., et al. 2006. TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Leukemia. 20: 280-285. (PubMed)
Hoyer, K., et al. 2005. T cell leukemia-1 modulates TCR signal strength and IFN-g levels through phosphatidylinositol 3-kinase and protein kinase c pathway activation. J. Immunol. 175: 864-873. (PubMed)
Herling, M., et al. 2003. TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+CD56+ blastic tumors of skin. Blood. 101: 5007-5009. (PubMed)
Takizawa J, Suzuki R, Kuroda H, Utsunomiya A, Kagami Y, Joh T, Aizawa Y, Ueda R, Seto M.
Expression of the TCL1 gene at 14q32 in B-cell malignancies but not in adult T-cell leukemia.
Jpn J Cancer Res. 1998 Jul;89(7):712-8. (PubMed)
